Seer (SEER) Competitors

Seer (NASDAQ:SEER) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

Do institutionals & insiders believe in SEER or CTKB?

75.2% of Seer shares are held by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are held by institutional investors. 11.3% of Seer shares are held by insiders. Comparatively, 10.3% of Cytek Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Do analysts rate SEER or CTKB?

Seer presently has a consensus price target of $3.00, suggesting a potential upside of 41.51%. Cytek Biosciences has a consensus price target of $5.60, suggesting a potential upside of 44.33%. Given Cytek Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Cytek Biosciences is more favorable than Seer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seer	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Is SEER or CTKB more profitable?

Cytek Biosciences has a net margin of -5.71% compared to Seer's net margin of -560.90%. Cytek Biosciences' return on equity of -2.90% beat Seer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seer	-560.90%	-24.69%	-22.13%
Cytek Biosciences	-5.71%	-2.90%	-2.30%

Which has more risk and volatility, SEER or CTKB?

Seer has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500. Comparatively, Cytek Biosciences has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500.

Does the media prefer SEER or CTKB?

In the previous week, Seer had 7 more articles in the media than Cytek Biosciences. MarketBeat recorded 11 mentions for Seer and 4 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 0.81 beat Seer's score of 0.22 indicating that Cytek Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seer	1 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cytek Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has better earnings and valuation, SEER or CTKB?

Cytek Biosciences has higher revenue and earnings than Seer. Cytek Biosciences is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seer	$14.17M	8.81	-$86.60M	-$1.41	-1.50
Cytek Biosciences	$200.45M	2.45	-$6.02M	-$0.09	-43.11

Summary

Cytek Biosciences beats Seer on 10 of the 16 factors compared between the two stocks.